• Xueyuan Zeng, Weimin Zhao, Yunlong Xu, Chengwei Zhang, Junliang Wu, Libo Xia, Ziyue Tian, and Jixiang Ren.
• Chinese Medicine Academy, Changchun University of Chinese Medicine, Changchun, Jilin Province, PR China.
• Medicine (Baltimore). 2021 Dec 10; 100 (49): e28172e28172.

BackgroundDyslipidemia is an important risk factor for atherosclerotic cardiovascular disease. Lycium barbarum L. are widely used as medicinal and functional food and may be particularly beneficial for patients with dyslipidemia. This systematic review protocol is designed to be used to evaluate the effects of Lycium barbarum L. on plasma lipid concentration through systematic reviews and meta-analysis.MethodsThe Following electronic databases will be searched from inception to October 2021: the China National Knowledge Infrastructure, PubMed, Cochrane Library, Web of Science, and Wan-fang database. All randomized controlled trial designs evaluated the effects of Lycium barbarum L. on plasma concentrations of lipids will be included. Two researchers will operate literature retrieval, screening, information extraction, quality assessment, and data analysis independently. The analysis will be conducted using Rstudio software (Version 1.4.1717).ResultsThe findings will be submitted to a peer-reviewed publication.ConclusionThis study will provide practical and targeted evidence in investigating the impact of Lycium barbarum L. on plasma lipid concentration in adults.Registration NumberINPLASY2021110043.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

26 keywords...

hide…